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Dendritic cells (DCs) arise from dedicated precursors and monocytes; however, the impact of these differen-
tial origins remain unclear. In this issue of Immunity, Siddiqui et al. (2010) describe a population of colitogenic
monocyte-derived DCs that propagate intestinal inflammation.The human intestinal tract covers the
area of a soccer pitch lined by a single
layer of columnar epithelial cells, which
forms the barrier between the gut lumen
and the host connective tissue. On top
of its constant exposure to dietary and
environmental antigens, the intestine
harbors an estimated 1014 commensal
bacteria. It is in this unique, complex
and vulnerable setting that inflammatory
bowel diseases (IBDs), such as Crohn’s
disease and ulcerative colitis, occur in
genetically predisposed individuals.More-
over, the intestinal tract presents also
a major site of pathogen entry requiring
an immune defense. To cope with these
challenges, the mammalian organism has
evolved robustly balanced immunemech-
anisms that provide protection against
invading pathogens, yet prevent detri-
mental collateral damage by inflammatory
responses against the commensal micro-
biota and food antigens. In this issue of
Immunity, Siddiqui et al. (2010) identify
a population of dendritic cells (DCs) that
mediate the inflammatory immune re-
sponses (Figure 1).
Recent findings indicate that intesti-
nal mononuclear phagocytes, comprising
DCs and macrophages, are crucial
for maintaining intestinal homeostasis.
Understanding how these cells interact
with the triad of microbiota, lymphocytes,
and the epithelium to shape intestinal
immune responses will be important for
identifying therapeutic IBD targets. The
intestinal mononuclear phagocyte com-
partment of the mouse in the steady state
is now mapped in fair detail. Murine intes-
tinal macrophages and DCs can be found
as resident cells in gut-associated lym-
phoid tissue (GALT), including isolated
lymphoid follicles (ILFs), Peyer’s patches
(PPs), and the gut-draining mesenteric
lymph nodes (MsnLNs). Moreover, mono-
nuclear phagocytes, and in particular502 Immunity 32, April 23, 2010 ª2010 ElsevDCs, are also highly abundant in the
loose connective tissue underlying the
columnar epithelial cell layer, the lamina
propria. As in other tissues, intestinal
mononuclear phagocytes have also been
subdivided according to characteristic
surface marker expression patterns, in
this case the integrins CD11c, CD11b,
and CD103, as well as the chemokine
receptor CX3CR1. Although these seem-
ingly arbitrary phenotypic categorizations
help researchers to communicate, the
subdivisions have recently been substan-
tiated by the discovery of discrete origins
of the intestinal DC subsets. All peripheral
mononuclear phagocytes are currently
considered derived from a dedicated
bone marrow resident precursor cell, the
so-called macrophage-DC precursors
(MDPs). However, in the bone marrow
MDPs give rise to two circulating DC
precursors. In steady state, lamina
propria-resident CX3CR1
+ DCs that can
uniquely penetrate the gut epithelium to
sense or sample gut content are gener-
ated from circulating blood monocytes,
specifically the Ly6Chi monocyte subset
(Bogunovic et al., 2009; Varol et al.,
2009a). In contrast, lamina propria-resi-
dent CD103+ CD11b+ DCs derive—like
their splenic counterpart, the classical
DCs (cDCs), and probably also GALT-
resident CD103+ CD11b DCs—from
recently described dedicated circulating
DC precursors (pre-cDCs [Liu et al.,
2009]). Importantly, recent data suggest
that only CD103+ CD11b+ DCs, but
not CX3CR1
+ DCs, migrate in a CCR7-
dependent manner to the mesenteric
LNs to promote T cell polarization toward
effector or regulatory fates (Schulz et al.,
2009). However, lamina propria CD103+
CD11b+ DCs seem to remember their
upbringing, as they remain conditioned
by the unique tissue environment of the
lamina propria and the overlying lumenier Inc.content-exposed epithel. Upon their ar-
rival in the draining mesenteric LNs,
CD103+ CD11b+ DCs are hence biased
to support the induction of T regulatory
cells and produce cytokine, such as
TGF-b, thereby contributing to the im-
muno-suppressive steady-state gut envi-
ronment.
As compared to our understanding of
mouse gut immune homeostasis that
extends to the interplay of the commensal
microbiota with the mucosal T cell com-
partment and T cell-dependent and -inde-
pendent IgA production by B cells, the
processes occurring in acute and chronic
gut inflammation remain still a black box.
Paradoxically, this is in stark contrast
to the data available of the human intes-
tinal landscape, in which most of our
knowledge stems from the analysis of
diseased tissue specimen isolated form
IBD patients.
Siddiqui et al. (2010) shed light into the
murine black box of gut inflammation.
Specifically, Siddiqui et al. identified
a population of E-cadherin+ DCs that
accumulates in the colon and the mesen-
teric LNs of mice suffering from colitis.
Interestingly though, the summoning of
E-cadherin+ monocyte-drived DCs was
restricted to T cell-driven colitis and
the engagement of CD40 on innate cells,
but did not occur in a merely innate Heli-
cobacter hepaticus-driven colitis model.
When taken into culture, E-cadherin+
DCs spontaneously produced substan-
tially more colitogenic cytokines, such
as IL-6 and IL-23, than conventional
MsnLN DCs. Moreover, E-cadherin+ DCs
also expressed a uniquely broad pattern
of Toll-like receptors (TLRs) rendering
them highly receptive for microbial prod-
ucts that could potentially exacerbate
their activities. Finally, Siddiqui et al.
showed that the transfer of bone marrow
culture-derived E-cadherin+ DCs, but not
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Figure 1. The Intestinal Dendritic Cell Compartment, in Steady State and under Chronic
Inflammation
Steady state intestinal DCs can be found in gut associated lymphoid tissue (GALT), including the ILFs and
dispersed in the lamina propria. CD11b+ CD103+ lamina propria DCs migrate in a CCR7-dependent
manner to the mesenteric lymph nodes, where they can promote antigen-specific tolerance or protective
immunity by stimulating naive T cells. CX3CR1
+ lamina propria DCs that can penetrate epithelium by
extending trans-epithelial dendrites do not emigrate, but seem to fulfill local functions in the maintenance
and re-activation of tissue resident memory, effector and regulatory T cells. CD11b- CD103+ DCs are
found in GALT. Siddiqui et al. establishes that under conditions of gut inflammation, monocyte-derived
E-cadherin+ DCs enter colon and MsnLNs and exacerbate inflammation by production of cytokines and
polarization of Th17 cells.
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(Rag-deficient) mice that had received
a CD45RBhi T cell graft significantly wors-
ened the colitis profile and boosted the
expansion of Th17 cells. Interestingly,
the authors provide furthermore both
in vitro and in vivo evidence that the accu-
mulation of these E-cadherin+ DCs is pre-
vented by the regulatory cytokine TGF-b,
as by transfer of T regulatory cells in the
course of their protection from colitis.
Collectively, these results highlight a key
detrimental role of these E-cadherin+
DCs in the perpetuation of the chronic
inflammatory process.
Phenotypic characteristics and their
chemokine receptor expression profile,
i.e., the lack of CCR7 that is required for
MsnLN homing, suggested to Siddiqui
et al. that the E-cadherin+ DCs had
not entered the LNs via the lymphatics,
but rather were blood derived. Indeed,
the authors directly corroborated this
assumption by performing adoptive
monocyte transfer experiments. More-
over, the results of these studies provide
evidence that the colitogenic E-cadherin+DCs are specifically derived from a partic-
ular Ly6C+ monocyte subset.
On the basis of histological findings
documenting massive cellular infiltra-
tions, circulating blood monocytes have
long been appreciated to play a prominent
role in inflammation. However, only re-
cently the study of these ephemeral cells
in animal models is taking off because of
seminal breakthroughs, such as the defi-
nition of the Ly6Chi and Ly6Clo monocyte
subsets (Geissmann et al., 2003) and
the development of novel experimental
approaches that has allowed studying of
the cells in a physiological context. The
prime task of monocytes had long been
considered the replenishment of the
short-lived peripheral DC compartment.
However, surprisingly, the in vivo studies
revealed that these cells did in fact not
give rise to what was considered classical
DCs. Rather monocytes differentiated in
the tissues into a distinct cell type, now
termed monocyte-derived DCs (MoDCs)
or ‘‘inflammatory DCs’’ (Shortman and
Naik, 2007). A specific nonredundant
function of the latter cells was first sug-Immunitygested by studies of the Pamer group,
who showed that Ly6Chi monocytes
differentiate in Listeria monocytogenes-
infected spleens into TNF-and-iNOS-
producing DCs (TIP-DCs), which critically
contribute to bacterial clearance (Serbina
et al., 2003). Moreover, Gunn and col-
leagues recently established that after
their recruitment to inflamed lymph
nodes, CCR2-expressing Ly6Chi mono-
cytes turn into IL-12-secreting DCs that
boost IFN-g production by antiviral
T cells (Nakano et al., 2009). Notably,
although originally termed ‘‘inflamma-
tory’’ (Geissmann et al., 2003), Ly6Chi
monocytes are far more versatile and
do not only exhibit proinflammatory fea-
tures. Rather, their activities are probably
dictated by the tissue context they en-
counter upon extravasation (Varol et al.,
2009b). In fact, in absence of inflamma-
tion, Ly6Chi monocytes return from the
blood to the bone marrow and convert
into Ly6Clo monocytes that can serve
as precursors of tissue macrophages.
Moreover, in DC-depleted animals, Ly6-
Chi monocytes can replenish the entire
CX3CR1
+ lamina propria DC compart-
ment while keeping gut homeostasis, as
long as they are balanced by CD103+
DCs (Varol et al., 2009a). Finally, emerging
evidence indicates that—in particular
under inflammatory conditions—mono-
cytes exert important accessory roles to
physiological processes in their own right,
i.e., beyond their classical role as precur-
sors of peripheral macrophages and DCs.
This includes their involvement in healing
processes at the myocard, the injured
muscle, and spinal cord, as well as critical
contributions to adult neovascularization
in tumors and tissue remodeling (Varol
et al., 2009b).
The importance of the study of Siddiqui
et al. lies in the fact that the authors estab-
lish an intriguing link between monocytes
and the perpetuation of chronic intestinal
inflammation and thereby extend pre-
vious studies on monocyte-derived DCs
(Nakano et al., 2009; Serbina et al.,
2003) to the clinically highly relevant
setting of IBDs. Notably, the monocyte
compartment is extremely short lived
and plastic, and hence probably readily
amenable to manipulation. The discovery
of the detrimental role of monocyte-
derived DCs in colitis might therefore
open new avenues for therapeutic inter-
ventions, including the interference with32, April 23, 2010 ª2010 Elsevier Inc. 503
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Previewsmonocyte recruitment, transient cell abla-
tion, and modulation of the monocyte
subset prevalence.
An important question though remains:
arguably the mere increase in production
rate and shortening of bone marrow
residency will modify the monocytes;
however, does the inflammatory condi-
tion have a defined qualitative impact on
the blood monocyte compartment? Or
do circulating cells remain naive in the
chronically inflamed organism and undis-
tinguishable from the steady state until
they reach the inflamed tissue? These
and other questions should spur efforts
to extend the study of mouse models of
chronic disease and inflammation to the
blood, as—to finish with Goethe—‘‘Blood504 Immunity 32, April 23, 2010 ª2010 Elsevis a quite special kind of juice’’ (Faust I,
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In this issue of Immunity, Tsai et al. (2010) demonstrate that low-avidity autoantigen-specific regulatory CD8+
T cells can reverse ongoing autoimmune disease and provide insight into the mechanism by which this is
achieved.Type 1 diabetes (T1D) is an autoimmune
disease in which the pancreatic beta cells
are selectively destroyed by the immune
system. It is a disease of juvenile onset
and affected individuals rely on exoge-
nous insulin for their survival. An enor-
mous amount of effort hasbeen expended
to develop strategies to prevent onset of
this autoimmune condition as well as to
cure established disease.
One of the major goals in developing
therapies for autoimmune diseases such
as T1D has been to target autoreactive
T cells and generate specific immune
tolerance while sparing the ability to
respond to exogenous antigens. Although
antigen-specific tolerogenic approaches
have been shown to prevent onset of
autoimmune pathology in animal models,
they have proved to be relatively ineffec-tive in the treatment of ongoing disease.
It had been hoped that although epitope
and antigen spread inevitably occurred
with ongoing tissue destruction, antigen-
specific approaches might be successful
through inducing ‘‘infectious’’ or ‘‘bystan-
der’’ suppression. In terms of clinical
application targeting antigen specific au-
toreactive cells has thus far proved disap-
pointing. Current therapeutic approaches
with efficacy on established autoimmune
disease include the use of monoclonal
antibodies such as anti-CD3 and anti-
CD20 (Chatenoud, 2010; Pescovitz et al.,
2009). The availability of an antigen-
specific therapy would represent a major
advance.
By using dextran-coated iron oxide
nanoparticles bearing diabetes-related
peptide MHC complexes (pMHC-NP),Tsai et al. (2010) in this issue of Immunity
have shown that this may be achievable.
The composition of the nanoparticle is
key to its efficacy. Different nanoparticles
have previously been used to expand
antigen-specific effector cells in vaccine
design and to target tumors in cancer
therapy. This study highlights the poten-
tial to use nanoparticles to downregulate
immune responses and provides a poten-
tial therapeutic approach for the treat-
ment of human autoimmune disease.
The NOD mouse spontaneously de-
velops type 1 diabetes and has been
used not only to explore the etiology
of disease development but also to
develop therapeutic strategies (Kikutani
and Makino, 1992). Studies in this model
have shown that there is a need for both
CD4+ T cells and CD8+ T cells in disease
